Abstract
Since 2000, we have introduced pre-operative chemotherapy including intra-peritoneal chemotherapy to patients with positive cytology and with no non-curative factors except peritoneum. Since 2006, we have started phase I trial with S-1 and intra-peritoneal chemotherapy with docetaxel to improve the efficacy and safety of the pre-operative regimen for advanced gastric cancer with peritoneal dissemination. The combination therapy with local and systemic chemotherapy is a promising regimen for gastric cancer with peritoneal dissemination.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Docetaxel
-
Dose-Response Relationship, Drug
-
Drug Combinations
-
Female
-
Humans
-
Male
-
Middle Aged
-
Neoadjuvant Therapy*
-
Neoplasm Staging
-
Oxonic Acid / adverse effects
-
Oxonic Acid / therapeutic use*
-
Peritoneal Neoplasms / drug therapy*
-
Peritoneal Neoplasms / secondary*
-
Stomach Neoplasms / drug therapy*
-
Stomach Neoplasms / pathology*
-
Stomach Neoplasms / surgery
-
Survival Rate
-
Taxoids / adverse effects
-
Taxoids / therapeutic use*
-
Tegafur / adverse effects
-
Tegafur / therapeutic use*
Substances
-
Drug Combinations
-
Taxoids
-
S 1 (combination)
-
Tegafur
-
Docetaxel
-
Oxonic Acid